Nice b/o for $ACAD ahead of MDD data this qtr (high failure rate in MDD, so a Nuplazid win isn't guaranteed). DRP FDA decision = major market expansion opp, though, so multiple 6-12 month catalysts that could keep the engine running. #biotech #stocks f/d = Long https://t.co/yKo2ihoL2o